Key Highlights

  • GNPX shares traded soft with no single verified catalyst explaining a specific session's move.
  • The company effected a 1-for-22 Reverse Stock Split on July 16, 2026, part of a broader effort to regain Nasdaq listing compliance.
  • Genprex announced a Manufacturing agreement in August 2026 to scale up its GPX-002 AAV diabetes gene-therapy program.
  • The company reported positive biomarker data at the ASCO meeting in May 2026 and a Roche Diagnostics collaboration on TROP2 biomarker validation in August.

A 1-for-22 reverse stock split, a Nasdaq compliance fight and a Market Value of only a few million dollars frame the current story at Genprex, Inc (NASDAQ: GNPX). The Austin-based gene-therapy developer has spent 2026 defending its listing while pushing cancer and diabetes programs forward. A soft Trading session is what surfaced the ticker, but the split, the Equity threshold it must clear and a run of Partnership news are what actually define where GNPX stands in September 2026.

Company and Latest Development

Genprex is a clinical-stage gene-therapy company developing treatments for cancer and diabetes. Its lead oncology asset, Reqorsa (quaratusugene ozeplasmid), uses a non-viral lipid-nanoparticle system to deliver a tumor-suppressor gene and is being studied in lung cancer alongside approved drugs, the Acclaim-1 trial pairing it with Tagrisso and the Acclaim-3 trial pairing it with Tecentriq. Its diabetes program, GPX-002, is an AAV-based therapy targeting Type 1 and Type 2 disease in preclinical models. On 18 August 2026 Genprex announced a manufacturing agreement with a contract developer to scale up the AAV diabetes program, covering process optimization and GMP-compliant bioreactor scale-up.

What Is Driving Attention Around GNPX?

The most concrete recent event is structural: on 16 July 2026 Genprex effected a 1-for-22 reverse stock split, a step companies typically take to lift a share price back above Nasdaq's $1 minimum. The reverse split accompanied a broader effort to regain compliance with Nasdaq listing standards, including a minimum stockholders'-equity requirement the company has said it needs to satisfy. No single verified catalyst explains a specific session; the reverse split, the compliance overhang and ongoing dilution risk are the durable pressures.

Key Numbers and Company Position

Following the 1-for-22 consolidation, shares traded in the low-single-digit-dollar range, yet the company's market Capitalization remained only a few million dollars, underscoring its nano-cap status. Genprex has disclosed a Nasdaq deficiency and outlined compliance steps tied to a minimum stockholders'-equity level. On the pipeline, the company reported positive biomarker data at the ASCO meeting in May 2026, secured a Canadian Patent allowance for Reqorsa combinations in June, and announced a Roche Diagnostics collaboration on TROP2 biomarker validation in August.

What Could Come Next?

The listing question dominates the near-term calendar: whether Genprex can demonstrate compliance with Nasdaq's equity requirement and sustain a share price above the minimum threshold following its split. Beyond that, investors may watch for clinical progress in the Acclaim lung-cancer trials, advancement of the GPX-002 diabetes program toward the clinic on the back of its new manufacturing agreement, and any additional financing, which small gene-therapy developers frequently require.

Risks to Watch

The risks are pronounced. A reverse split does not by itself fix an equity shortfall, and failure to regain or maintain compliance could threaten the Nasdaq listing. As a pre-commercial gene-therapy company, Genprex faces high clinical-trial risk, a lengthy regulatory path and a persistent need for capital that can dilute existing holders.

A Stockholders'-Equity Test Looms Over the Pipeline Progress

Genprex heads into late 2026 with a reset share count, a defined Nasdaq compliance task and a pipeline spanning lung-cancer and diabetes gene therapies. The company has kept partnership and patent news flowing, but its listing status and funding position remain the central uncertainties. Investors may be watching the equity-compliance outcome, progress in the Acclaim trials and diabetes-program manufacturing the factors that will chart GNPX's course from here.